Why the study?
During the COVID-19 pandemic, the pharmaco-invasive approach played a vital role in managing STEMI, especially where primary PCI was unavailable.
Does tenecteplase improve outcomes compared to streptokinase in STEMI patients when primary PCI is unavailable?
Does tenecteplase improve outcomes compared to streptokinase in STEMI patients when primary PCI is unavailable?
In a retrospective study of STEMI patients during the COVID-19 pandemic at a center without primary PCI, there was no significant difference in outcomes between thrombolysis with streptokinase versus tenecteplase.
STEMI thrombolysis outcomes similar with SK versus TNK; should not yet change practice and leaves randomized comparison open.
During the COVID-19 pandemic, the pharmaco-invasive approach in the management of ST Elevation Myocardial Infarction (STEMI) played a vital role in saving many lives. A retrospective observational study was conducted wherein 134 patients presenting with STEMI between (Dec 2019-Mar 2022) were thrombolysed with either streptokinase or tenecteplase in a centre where primary PCI was not available. There was no significant difference in the outcomes and their predictors between the SK and TNK groups. A prospective study with a larger sample size in the Indian population will be able to provide more substantial and promising results for further interventions.
No takes yet. Share an insight, caveat, or question.
Karanth et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: